Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Express Scripts
Colorcon
McKinsey
Dow

Last Updated: May 17, 2022

VIMOVO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Vimovo, and what generic alternatives are available?

Vimovo is a drug marketed by Horizon and is included in one NDA. There are nine patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-two patent family members in twenty-four countries.

The generic ingredient in VIMOVO is esomeprazole magnesium; naproxen. There are seventy-four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the esomeprazole magnesium; naproxen profile page.

DrugPatentWatch® Generic Entry Outlook for Vimovo

There have been twenty-nine patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (esomeprazole magnesium; naproxen), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for VIMOVO
Drug Prices for VIMOVO

See drug prices for VIMOVO

Drug Sales Revenue Trends for VIMOVO

See drug sales revenues for VIMOVO

Paragraph IV (Patent) Challenges for VIMOVO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIMOVO Delayed-release Tablets esomeprazole magnesium; naproxen 375 mg/20 mg and 500 mg/20 mg 022511 1 2010-11-05

US Patents and Regulatory Information for VIMOVO

VIMOVO is protected by nine US patents.

Patents protecting VIMOVO

Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

Pharmaceutical compositions for the coordinated delivery of NSAIDS
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER

Method for treating a patient at risk for developing an NSAID-associated ulcer
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN

Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT

Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT

Method for delivering a pharmaceutical composition to patient in need thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT

Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Method for delivering a pharmaceutical composition to patient in need thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT

Pharmaceutical compositions for the coordinated delivery of NSAIDs
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIMOVO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 See Plans and Pricing See Plans and Pricing
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 See Plans and Pricing See Plans and Pricing
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 See Plans and Pricing See Plans and Pricing
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-001 Apr 30, 2010 See Plans and Pricing See Plans and Pricing
Horizon VIMOVO esomeprazole magnesium; naproxen TABLET, DELAYED RELEASE;ORAL 022511-002 Apr 30, 2010 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for VIMOVO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0984957 2012/048 Ireland See Plans and Pricing PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812
0984957 430 Finland See Plans and Pricing
1411900 2011/016 Ireland See Plans and Pricing PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105
1411900 1190013-1 Sweden See Plans and Pricing PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
0124495 SPC/GB01/006 United Kingdom See Plans and Pricing PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Baxter
Moodys
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.